Tlando (Testosterone Undecanoate) Patent Expiration, LOE Window & CMS Spending
Tlando (Testosterone Undecanoate) by Verity: FDA Orange Book LOE 2041-04-28, 0 AB generics, $872K 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Verity |
| FDA Application & Pathway | N208088 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2041-04-28 |
| Orange Book Patents (*PED Extensions) | 15 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $872K |
| 2024 Medicare Part D Spend | $671K |
| 2024 Medicaid Spend | $201K |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 29.2% 2-yr change) |